Vascular calcification in chronic renal failure

Area of Science:

• Nephrology
• Vascular Biology
• Cardiovascular Medicine

Background:

• Vascular calcification (VC) prevalence and severity escalate with dialysis duration.
• Medial artery calcification is linked to impaired vascular compliance and heightened cardiovascular mortality risk.
• Coronary artery calcification is frequent in end-stage renal disease, with contributions from both intimal and medial layers needing further study.

Purpose of the Study:

• To review the drivers and clinical implications of vascular calcification in patients undergoing dialysis.
• To explore the role of phosphate, calcium, and specific medications in the pathogenesis and progression of VC.
• To discuss the management of calcific uraemic arteriolopathy.

Main Methods:

• Review of current evidence on vascular calcification in end-stage renal disease.
• Analysis of in vitro and clinical data implicating phosphate and calcium metabolism.
• Evaluation of the impact of phosphate binders (calcium-based vs. sevelamer) and warfarin on VC progression.

Main Results:

• High extracellular phosphate concentration induces phenotypic changes in vascular cells, supporting hyperphosphatemia as a key driver of VC.
• Sevelamer use significantly retards coronary and aortic calcification progression compared to calcium-based phosphate binders.
• The role of warfarin and the mechanisms of calcium balance in promoting VC remain uncertain.

Conclusions:

• Hyperphosphatemia is a major contributor to vascular calcification in dialysis patients.
• Phosphate management is critical, with sevelamer showing a benefit over calcium-based binders in retarding VC.
• Further research is needed to clarify the roles of warfarin, calcium balance, and other potential treatments in VC.